T790M mutation and clinical outcomes with osimertinib in patients with epidermal growth factor receptor-mutant nonsmall cell lung cancer

Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors TKIs) are highly effective in EGFR-mutant advanced lung cancer. The most common resistance mechanism to EGFR-TKI is the development of T790M mutation in Exon 20. Osimertinib, a highly selective EGFR-TKI, has been approv...

Full description

Bibliographic Details

Published in:	Indian Journal of Medical and Paediatric Oncology
Main Authors:	Ravi Jaiswal, Rakesh Pinninti, M VT Krishna Mohan, A Santa, Pavan Kumar Boyella, Lavanya Nambaru, Sudha S Murthy, K Veeriah Chowdary, Senthil Rajappa
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2019-01-01
Subjects:	Epidermal growth factor receptor liquid biopsy lung cancer osimertinib re-biopsy T790M
Online Access:	http://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=1;spage=73;epage=78;aulast=